Sort
48,018 grants matching “immunotherapy”
Development of Immunologic therapies against uveitis
$576,011Charles E Egwuagu · National Eye Institute · ZIA · FY2025 · EY
Computational imaging approaches to personalized gastric cancer treatment
$575,981Ruijiang Li · Stanford University · R01 · FY2025 · CA
Engaging immunosuppressive myeloid cells in the TME for the treatment of pancreatic cancer
$575,967Jeffrey Victor Ravetch · Rockefeller University · R01 · FY2021 · CA
Dual-payload antibody-drug conjugate for chemo-immunotherapy of triple-negative breast cancers
$575,907Xiaoguang Margaret Liu · Ohio State University · R01 · FY2025 · CA
The Antigen Targeting Core
$575,890Maria Parkhurst · Division Of Basic Sciences - Nci · ZIC · FY2025 · CA
Non-invasive imaging of the anti-tumor immune response
$575,887Hidde L Ploegh · Boston Children'S Hospital · R01 · FY2023 · CA
Non-invasive imaging of the anti-tumor immune response
$575,887Hidde L Ploegh · Boston Children'S Hospital · R01 · FY2022 · CA
Novel CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy
$575,716Farrokh Dehdashti · Washington University · R01 · FY2019 · CA
Peptoid conjugates targeting prostate cancer
$575,698Michael J Garabedian · New York University School Of Medicine · R01 · FY2025 · CA
Mechanisms of HBV Functional Cure During Tenofovir-based ART in HIV/HBV Coinfection
$575,680Michael Jeffrey Vinikoor · University Of Alabama At Birmingham · R01 · FY2023 · AI
Immune Mechanisms in Ocular Graft versus Host Disease
$575,657Robert Benjamin Levy · University Of Miami School Of Medicine · R01 · FY2017 · EY
CANCER AND STROMA-TARGETED IMMUNOTHERAPY WITH A GENETICALLY MODIFIED DC VACCINE
$575,626Baylor College Of Medicine · · FY2010 · Department of the Army
The Role of CD3z ITAM (Immunoreceptor Tyrosine-Based Activation Motif) diversity in CAR T cell Force and Function
$575,619Matthew Bettini · University Of Utah · R01 · FY2024 · CA
Dual p300 and p53 reactivation in HPV+ head and neck cancer
$575,570Quintin Pan · Case Western Reserve University · R01 · FY2024 · DE
Biospecimen Unit
$575,561Bruce E. Johnson · Dana-Farber Cancer Inst · U2C · FY2021 · CA
Development of tolerogenic Factor VIII as immunotherapy to prevent inhibitor development in Hemophilia A
$575,469Sathy Venkat Balu-Iyer · State University Of New York At Buffalo · R61 · FY2023 · HL
Activating Native Tumor Immunity with IL-33 Armored CARs
$575,420Yina Hsing Huang · Dartmouth College · R01 · FY2025 · CA
Reorienting the Glioblastoma Microenvironment to Respond to Immunotherapy
$575,374Mary Helen Barcellos-Hoff · University Of California, San Francisco · R01 · FY2022 · NS
Enhancing Innate and Adaptive Immunity to Improve Sepsis Survival
$575,370Richard Samuel Hotchkiss · Washington University · R35 · FY2024 · GM
Enhancing Innate and Adaptive Immunity to Improve Sepsis Survival
$575,370Richard Samuel Hotchkiss · Washington University · R35 · FY2025 · GM
Purging Latent HIV Reservoirs through a Combination HIV Therapeutic
$575,354Trevor P. Castor · Aphios Corporation · R43 · FY2017 · AI
Autoimmune vitiligo and tolerance in the immune response to a melanoma antigen
$575,287Victor H. Engelhard · University Of Virginia · R01 · FY2009 · AI
Immune Profiling
$575,268Christian P Larsen · Emory University · U19 · FY2009 · AI
Engineered Nano-formulations for STING Activation
$575,252James J. Moon · University Of Michigan At Ann Arbor · R01 · FY2023 · DE
Molecular and immunological heterogeneity of Small Cell Lung Cancer (SCLC) and its impact on relapse and therapeutic response
$575,245Lauren Averett Byers · University Of Tx Md Anderson Can Ctr · U01 · FY2024 · CA